MX2022016197A - Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. - Google Patents
Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos.Info
- Publication number
- MX2022016197A MX2022016197A MX2022016197A MX2022016197A MX2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antibody fragments
- immunoconjugates
- chain variable
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040913P | 2020-06-18 | 2020-06-18 | |
| PCT/US2021/037400 WO2021257542A1 (en) | 2020-06-18 | 2021-06-15 | Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016197A true MX2022016197A (es) | 2023-04-05 |
Family
ID=79268294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016197A MX2022016197A (es) | 2020-06-18 | 2021-06-15 | Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230242662A1 (https=) |
| EP (1) | EP4168452A4 (https=) |
| JP (2) | JP7795206B2 (https=) |
| KR (1) | KR20230023800A (https=) |
| CN (1) | CN115702167A (https=) |
| AU (1) | AU2021292486A1 (https=) |
| CA (1) | CA3182384A1 (https=) |
| IL (1) | IL298902A (https=) |
| MX (1) | MX2022016197A (https=) |
| TW (1) | TWI906314B (https=) |
| WO (1) | WO2021257542A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| CA2810016A1 (en) * | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Novel modulators and methods of use |
| CN107135654B (zh) * | 2014-09-12 | 2021-10-29 | 加利福尼亚大学董事会 | 巨胞饮人类抗cd46抗体和靶向癌症疗法 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2017078839A1 (en) * | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
| KR102873209B1 (ko) * | 2016-08-31 | 2025-10-17 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 폴리펩티드 및 이를 제조하는 방법 |
| ES3005158T3 (en) * | 2016-11-11 | 2025-03-14 | Univ California | Anti-cd46 antibodies and methods of use |
| CN109535260B (zh) * | 2018-11-22 | 2021-08-10 | 东南大学 | 一种靶向cd46的人源嵌合抗原受体及其应用 |
-
2021
- 2021-06-15 CA CA3182384A patent/CA3182384A1/en active Pending
- 2021-06-15 AU AU2021292486A patent/AU2021292486A1/en active Pending
- 2021-06-15 JP JP2022577490A patent/JP7795206B2/ja active Active
- 2021-06-15 WO PCT/US2021/037400 patent/WO2021257542A1/en not_active Ceased
- 2021-06-15 IL IL298902A patent/IL298902A/en unknown
- 2021-06-15 KR KR1020237001966A patent/KR20230023800A/ko active Pending
- 2021-06-15 EP EP21824799.7A patent/EP4168452A4/en active Pending
- 2021-06-15 US US18/002,010 patent/US20230242662A1/en active Pending
- 2021-06-15 MX MX2022016197A patent/MX2022016197A/es unknown
- 2021-06-15 CN CN202180043149.6A patent/CN115702167A/zh active Pending
- 2021-06-18 TW TW110122286A patent/TWI906314B/zh active
-
2025
- 2025-12-12 JP JP2025247571A patent/JP2026053430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026053430A (ja) | 2026-03-25 |
| KR20230023800A (ko) | 2023-02-17 |
| IL298902A (en) | 2023-02-01 |
| TWI906314B (zh) | 2025-12-01 |
| CN115702167A (zh) | 2023-02-14 |
| JP2023531189A (ja) | 2023-07-21 |
| WO2021257542A1 (en) | 2021-12-23 |
| EP4168452A1 (en) | 2023-04-26 |
| AU2021292486A1 (en) | 2023-02-09 |
| TW202214696A (zh) | 2022-04-16 |
| EP4168452A4 (en) | 2024-07-10 |
| JP7795206B2 (ja) | 2026-01-07 |
| CA3182384A1 (en) | 2021-12-23 |
| US20230242662A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
| MX2022010487A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
| MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| MY205933A (en) | Sirp-alpha binding proteins and methods of use thereof | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| MX377605B (es) | Inmunoglobulina híbrida conteniendo un enlace no-peptidílico. | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| TN2010000197A1 (en) | New antibodies specific of the beta -amyloid peptides and their uses as diagnostic agents or drugs | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
| ZA202203460B (en) | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) | |
| SG10201801219VA (en) | Anti-HER2 Antibodies | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение |